PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-38.56%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-7.06%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-7.06%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
7.02%
EBITDA growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Operating income growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
148.79%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
10.36%
Pre-tax income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.36%
Net income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
28.30%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
28.30%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
24.68%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
24.68%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.